China Abiraterone Markets Investigation Report, 2016-2020 & 2021-2025: A CYP17 Inhibitor, Which is Mainly Clinically Used to Treat Prostate Cancer Patients - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Abiraterone Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
Abiraterone is a CYP17 inhibitor, which is mainly clinically used to treat prostate cancer patients. Its product ZYTIGA was developed by Janssen-Cilag International NV(a subsidiary of Johnson & Johnson). In 2015, Abiraterone entered the Chinese market.
The analyst analyzes that from 2021 to 2025, Abiraterone's sales in China will continue to grow as the improvement of COVID-19 epidemic. According to data from China National Cancer Registration Institute, prostate cancer has become the most common tumor in male urinary malignancies since 2008. As the incidence and mortality of this cancer continue to rise, and its sales will also increase.
As of 2020, in addition to Janssen-Cilag International NV, the main manufacturers of Abiraterone in China are Chengdu Suncadia Medicine Co., Ltd., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangxi Shanxiang Pharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.
According to the market research, from 2016 to 2019, Abiraterone's sales in the Chinese market have shown an upward trend. In 2017, the price of Abiraterone dropped and it was included in China's national medical insurance. Therefore, the sales of Abiraterone in the Chinese market increased the most significantly from 2017 to 2019.
The annual sales revenue in 2019 is CNY566.84 million, which increased over 30 times compared to that in 2016. The outbreak of the COVID-19 epidemic in 2020 has impacted the overall diagnosis and treatment business of Chinese hospitals, so the sales value of Abiraterone in the Chinese market declined slightly in 2020.
The CAGR of Abiraterone sales value in the Chinese market from 2016 to 2020 is 140.7%.
- The impact of COVID-19 on China's Abiraterone market
- Sales value of China's Abiraterone 2016-2020
- Competitive landscape of China's Abiraterone market
- Prices of Abiraterone in China
- Prices of Abiraterone in China by regions and manufacturers
- Analysis of factors affecting the development of China's Abiraterone market
- Prospect of China's Abiraterone market from 2021 to 2025
Key Topics Covered:
1 Relevant Concepts of Abiraterone
1.1 Indications for Abiraterone
1.2 Development of Abiraterone in China
1.3 Governmental Approval of Abiraterone in China
1.4 The Impact of COVID-19 on Abiraterone sales in China
2 Sales of Abiraterone in China, 2016-2020
2.1 Sales Value of Abiraterone
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2 Sales Volume of Abiraterone
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Abiraterone by Dosage Form in China, 2016-2020
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Abiraterone Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Abiraterone Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Janssen-Cilag International NV(BE)
3.2.1 Enterprise Profile
3.2.2 Sales of ZYTIGA (Janssen-Cilag International NV(BE)'s Abiraterone) in China
3.3 Chengdu Suncadia Medicine Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Aisente (Chengdu Suncadia Medicine Co., Ltd.'s Abiraterone) in China
3.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Qingkeshu (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Abiraterone) in China
3.5 Jiangxi Shanxiang Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Abiraterone (Jiangxi Shanxiang Pharmaceutical Co., Ltd.'s Abiraterone) in China
3.6 Qilu Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Zhuorong (Qilu Pharmaceutical Co., Ltd.'s Abiraterone) in China
4 Prices of Abiraterone for Different Manufacturers in China, 2020-2021
4.1 Janssen-Cilag International NV(BE) (ZYTIGA)
4.2 Chengdu Suncadia Medicine Co., Ltd. (Aisente)
4.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.(Qingkeshu)
4.4 Jiangxi Shanxiang Pharmaceutical Co., Ltd.
4.5 Qilu Pharmaceutical Co., Ltd.(Zhuorong)
5 Prospect of Chinese Abiraterone Market, 2021-2025
5.1 Influential Factors of Chinese Abiraterone Market Development
5.1.1 The Impact of COVID-19 on Chinese Abiraterone Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/vhvzf7
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900